Right, this statement is just advertising or positiong to investors. AC5 is a device platform technology licensed from MIT. ARTH is performing no development of drugs using cells or large moleculaes. This doesn't mean the tech isn't useful; I was reactiong to post that stated that $33M of spend is not a lot for a biotech firm. What is concerning is the amount & percentage of spend for G&A; this doesn;t get anyone products.
News 
Market Data 
Discover 
